A hard lesson learnt: Commonwealth v Sanofi

In June this year, the first Full Federal Court decision on this issue was handed down following a ten-year damages battle between the Commonwealth and Sanofi relating to Apotex’s ‘delayed’ launch of generic clopidogrel following PI.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

‘Doing more with less’: In-house counsel on budgets and strategy

22 October 2025 Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.

Biotechnology

An update on patenting in Ukraine, Russia and Eurasia

2 September 2025 Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.

Biotechnology

Synthego clears rival’s patents from CRISPR market at Fed Circ

12 June 2025 Judges uphold PTAB’s finding that two Agilent patents are invalid | All claims of patents, which cover guide RNAs, found to be anticipated by prior art.

More features

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

From migraine drugs to COVID vaccine spats, US lawsuits pile up

How AI will be shaped by legal and regulatory developments in 2026

Key EU and UK regulatory changes to watch for in 2026

From Edwards to Insulet: Three key medical device cases of 2025

5 ways the USPTO director is changing US innovation

Mirum targets generics in quartet of suits over liver treatment

A hard lesson learnt: Commonwealth v Sanofi

More on this story

Editor's picks

Editor's picks

More features